Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy’s Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Indian generic drug maker achieved the milestone on acquisitions supported by a “strong and profitable” growth engine.
Advertisement

Related Content

Indian Companies Ramping Up For Follow-On Biologics
Indian Companies Ramping Up For Follow-On Biologics
Indian Companies Ramping Up For Follow-On Biologics
Ranbaxy’s First Biosimilar Target Will Be Amgen’s Neupogen
Ranbaxy’s First Biosimilar Target Will Be Amgen’s Neupogen
Par Launches Generic Zofran ODT Following FDA Clearance
Indian Pharma Focusing On R&D, Licensing – Ranbaxy Exec
Generic Giant: Dr. Reddy’s Acquires Betapharm Group
If You Can't Beat Em'…Merck Signs Authorized Generic Deal For Zocor And Proscar
If You Can't Beat Em'…Merck Signs Authorized Generic Deal For Zocor And Proscar

Topics

Advertisement
UsernamePublicRestriction

Register

PS065059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel